I'm not ok with the increased # of authorized shares. We
I'm not ok with the increased # of authorized shares. We just voted end of last year to allow for the 200million shares. We were told they would be used sparingly. to start talking about the need for more for the same reason that was given last year is basically admitting they did not use the last 200 million shares sparingly and/or they catalyst that was to be born out of the flexibility having those shares did not happen.
We don't have any trials going on, we don't have the expenses we once had. Management needs to deliver on what the last share float increase was suppose to do. I don't care if the whole team and the BOD work for free, they owe us.
I don't understand how re-formatting the Amarex data takes this long, I don't understand why the Brazil trials were clinical holds last CC and now they are just pauses from DSMC? Also, the big one, Is why the clincal hold has not been resolve in the HIV BLA. It is just un-acceptable that this is holding everything up and they did not clearly state that they have everything together and just need the FDA to lift the Clinical hold. The management team must resolve this and I have zero interest in excuses about past management.
As for Dr Recknor's excitement about the data from the Nash trial, I was left wondering how we are just now figuring out how this drug works? It would seem that the FDA just does not look at the results of a trial, they want reasons why it worked and why different doses do different things. At this point we have done many trials and I get the feeling the FDA is frustrated asking the same questions. We have to know everything about our own product, to be still learning after 8+ years just says we did not really design the right trials and do the correct research to get FDA approval.
We paid for this, time to get our moneys worth.
8
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...
Continue Reading
Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...
Continue Reading
Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...
Continue Reading
Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...
Continue Reading
Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...
Continue Reading
Top 5 Most Recently Viewed Articles
Reworld-SEMASS Workers Unionize for a Stronger Future 120 Sanitation Workers Organize with Local 59 for Strong Union Contract Recently, sanitation workers at Reworld-SEMASS made a significant move by voting to join Teamsters Local 59. This decision reflects the collective desire of 120 auxiliary operators, equipment operators, loader operators, and rail tippers to secure...
Continue Reading
Euroseas Ltd. Announces New Charter Agreement Euroseas Ltd. (NASDAQ: ESEA), an established operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, is thrilled to announce the signing of a significant time charter for their 1,732 teu feeder containership, known as M/V Jonathan P. This new contract spans a duration of 11 to...
Continue Reading
Shifts in SEC Leadership and Their Potential Impact on Cryptocurrency The cryptocurrency industry is facing anticipated changes as discussions about the future of the Securities and Exchange Commission (SEC) unfold. According to insights shared by Pantera Capital's chief legal officer, Katrina Paglia, significant changes may occur once Gary Gensler steps down from his...
Continue Reading
Anticipation Builds for Terra Innovatum Global’s Financial Results Terra Innovatum Global N.V. (NASDAQ: NKLR), a pioneer in the micro-modular nuclear reactor space, is gearing up to unveil its third quarter financial results for the fiscal year 2025. This eagerly awaited announcement is set to take place just before the start of trading on an upcoming Monday. Who Will...
Continue Reading
Magnachip's Expansion in MOSFET Production Magnachip Semiconductor Corporation (NYSE: MX) is significantly advancing its production capabilities with the latest expansion of its 7th generation MXT LV MOSFETs. This strategic move aligns perfectly with the rising demand for compact and efficient low voltage MOSFETs utilized in a variety of advanced mobile devices today....
Continue Reading